<DOC>
	<DOCNO>NCT01467232</DOCNO>
	<brief_summary>Following myocardial infarct , cellular therapy potential approach repopulate injured myocardium , treat heart failure restore cardiac function . The purpose study assess safety , feasibility efficacy intramyocardial delivery select autologous CD133+ bone marrow stem cell time coronary artery bypass graft patient chronic ischemic cardiomyopathy .</brief_summary>
	<brief_title>IMPACT-CABG Trial : IMPlantation Autologous CD133+ sTem Cells Patients Undergoing Coronary Artery Bypass Grafting</brief_title>
	<detailed_description>CD133+ well characterize distinct early progenitor group stem cell possess high engraftment , pluripotent angiogenic capacity prove valuable cardiac repair promote neovascularization , inhibition apoptosis cardiomyogenesis . The investigator propose research protocol involve patient chronic ischemic heart disease leave ventricular dysfunction undergo coronary artery bypass grafting ( CABG ) . In phase II clinical trial , prospective , randomize , 2 arm , double-blind , placebo-controlled study , investigator assess safety , feasibility functional effect intra-myocardial injection highly select autologous CD133+ bone marrow stem cell placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Age ≥18 year , ≤75 year . Patients severe chronic ischemic cardiomyopathy manifest Canadian Cardiovascular Society ( CCS ) class II great angina , and/or New York Heart Association ( NYHA ) class II great dyspnea , AND undergone diagnostic coronary angiography demonstrate ≥70 % diameter narrow least two major coronary artery branch ≥50 % diameter narrowing leave main coronary artery . Significant leave ventricular systolic dysfunction evaluate echocardiography LV angiography ( LV ejection fraction ≤45 % ≥25 % ) due prior myocardial infarction . This area leave ventricular dysfunction akinetic severely hypokinetic , dyskinetic aneurysmal , assess echocardiography LV angiogram . No contraindication exclusion ( see ) . Willingness participate ability provide inform consent . contraindication magnetic resonance imaging ( MRI ) include presence implantable cardiac defibrillator ( ICD ) permanent pacemaker ( PPM ) , case anticipate ICD PPM implant prior 6 month followup claustrophobia ( thus preclude performance followup MRI scan ) . Need urgent emergent revascularization . Anticipated concomitant surgical procedure time CABG ( e.g . valve repair replacement , aneurysm resection , etc. ) . Hemodynamically unstable patient , defined heart rate ≤40/min ≥100/min , and/or systolic blood pressure &lt; 90 mmHg ≥200 mmHg , and/or ongoing need intravenous inotropic vasopressor medication . Patients confirm myocardial infarction within 14 day , and/or rise cardiac biomarker protein ( i.e . CKMB troponin ) , and/or worsen ECG change . Prior CABG surgery . Stroke within 3 month prior plan CABG . Immunosuppressive medication ( e.g . prednisone , cyclophosphamide , etanercept , etc . ) Severe chronic renal insufficiency ( serum creatinine ≥ 200 mmol/dl need dialysis ) , liver disease , ( diagnosis cirrhosis , chronic hepatitis , elevate serum transaminase ≥3 time upper limit normal ) , cerebrovascular disease require concomitant carotid endarterectomy , peripheral arterial disease ( claudication primary factor limit activity ) , active nondermatological malignancy require ongoing treatment , condition would place patient increase risk complication first 6 month procedure judgement attend cardiologist cardiac surgeon . Contraindication bone marrow aspiration ( Thrombocytopenia &lt; 50,000 mm3 , INR &gt; 2.0 ) . Hemoglobin le 10g/dL , white blood cell count less 4,000/mm3 , absolute neutrophil count le 1500/mm3 Active infection , temperature great 37.5°C within 48 hour prior surgery unexplained white blood cell count excess 10,000/mm3 Myelodysplastic syndrome Significant cognitive impairment Any condition associate life expectancy le 6 month Known allergic reaction contraindication component CD133+ enrich cell Participation study History severe ventricular tachyarrhythmia 's require treatment Positive laboratory test result history syphilis , Hepatitis B Virus , Hepatitis C Virus , Human TLymphotropic Virus Type 1 2 , Human Immunodeficiency Virus . Pregnant woman Inability unwillingness provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>